Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks

Article Abstract:

The analysis of pooled safety data from the pivotal phase three T-20 Versus Optimized Background Regimen Only (TORO) trials indicates that enfuvirtide is a well-tolerated antiretroviral agent with a maintained safety profile over 48 weeks in treatment-experienced HIV-1-infected adults. It is found that the rates of other adverse agents favored enfuvirtide or were generally comparable between treatments.

Author: Henry, Keith, Clotet, Bonaventura, Nelson, Mark, Cooper, David, Lazzarin, Adriano, Smiley, Lynn, Montaner, Julio, Lange, Joep, Delfraissy, Jean-Francois, Cohen, Calvin, Salgo, Miklos P., Katlama, Christine, Piliero, Peter, Jain Chung, Walmsley, Sharon, DeMasi, Ralph, O'Hearn, Mary, Drobnes, Claude, Eron, Joseph J., Jr., Stellbrink, Hans-Jurgen, Arasteh, Keikawus, Troittier, Benoit, Reynes, Jacues, Lalezari, Jacob, Kuritzkes, Daniel, Kinchelow, Tosca, Bertasso, Anne, Labriola-Tompkins, Emily, Shikhman, Anna, Atkins, Belinda, Bourdeau, Laurence, Natale, Christopher, Hughes, Fiona, Guimaraes, Denise, Bader-Weder, Silvia
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
Care and treatment, Drug therapy, Combination, Combination drug therapy

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen into 1 and 2 clinical trials

Article Abstract:

Exploratory analyses to compare treatment effects between the enfuvirtide and control groups by different factors after 48 weeks that were carried out are discussed. It was demonstrated that the efficacy to enfuvirtide is durable plus optimized background over 48 weeks.

Author: Cooper, David A., Henry, Keith, Kuritzkes, Daniel R., Clotet, Bonaventura, Reynes, Jacques, Nelson, Mark, Montaner, Julio S.G., Lazzarin, Adriano, Lange, Joep, Delfraissy, Jean-Francois, Cohen, Calvin, Salgo, Miklos P., Katlama, Christine, Lalezari, Jacob P., Jain Chung, O'Hearn, Mary, Donatacci, Lucille, Piliero, Peter J., Eron, Joseph J., Jr., Stellbrink, Hans-Jurgen, Wat, Cynthia, Arasteh, Keikawus, Buss, Neil E., Gulmaraes, Denise, Demasi, Ralph
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
Government regulation, Drug therapy, Licensing, certification and accreditation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, HIV infection, HIV infections, Antiviral agents, Antiretroviral agents
Similar abstracts:
  • Abstracts: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.